| 1 | Inactivated virus | CoronaVac; inactivated SARS-CoV-2 vaccine (vero cell) | 2 | Day 0 + 14 | IM | Sinovac Research and Development Co., Ltd | Phase 4 | [32] |
| 2 | Inactivated virus | Inactivated SARS-CoV-2 vaccine (Vero cell) | 2 | Day 0 + 21 | IM | Sinopharm; | Phase 4 | A |
| 3 | Inactivated virus | Inactivated SARS-CoV-2 vaccine (Vero cell), vaccine name BBIBP-CorV | 2 | Day 0 + 21 | IM | Sinopharm; | Phase 4 | [31] |
| 14 | Inactivated virus | SARS-CoV-2 vaccine (vero cells) | 2 | Day 0 + 28 | IM | Institute of Medical Biology + Chinese Academy of Medical Sciences | Phase 3 | B |
| 15 | Inactivated virus | QazCovid-in® - COVID-19 inactivated vaccine | 2 | Day 0 + 21 | IM | Research Institute for Biological Safety Problems, Rep of Kazakhstan | Phase 3 | C |
| 20 | Inactivated virus | BBV152 vaccine | 2 | Day 0 + 14 | IM | Bharat Biotech International Limited | Phase 3 | D |
| 25 | Inactivated virus | Inactivated SARS-CoV-2 vaccine (Vero cell) | 2 | Day 0 + 28 | IM | Shenzhen Kangtai Biological Products Co., Ltd. | Phase 3 | E |
| 56 | Inactivated virus | VLA2001 | 2 | Day 0 + 21 | IM | Valneva, National Institute for Health Research, United Kingdom | Phase 3 | F |
| 63 | Inactivated virus | TURKOVAC, inactivated virus | 2 | Day 0 + 21 | IM | Erciyes University and the Health Institutes of Turkey (TUSEB) | Phase 3 | G |
| 4 | Viral vector (non-replicating) | ChAdOx1-S - (AZD1222) | 1-2 | Day 0 + 28 | IM | AstraZeneca + University of Oxford | Phase 4 | [15] |
| 5 | Viral vector (non -replicating) | Recombinant novel coronavirus vaccine (adenovirus type 5 vector) | 1 | Day 0 | IM | CanSino Biological Inc./Beijing Institute of Biotechnology | Phase 4 | [13, 14] |
| 6 | Viral vector (non -replicating) | Recombinant COVID-19 vaccine (adenovirus type 5 vector) for Inhalation (Ad5-nCoV-IH) | 1 | Day 0 | IH | CanSino Biological Inc./Beijing Institute of Biotechnology | Phase 3 | H |
| 7 | Viral vector (non -replicating) | Gam-COVID-Vac Adeno-based (rAd26-S+rAd5-S) | 2 | Day 0 + 21 | IM | Gamaleya Research Institute ; Health Ministry of the Russian Federation | Phase 3 | [10] |
| 8 | Viral vector (non -replicating) | Ad26.COV2.S | 1-2 | Day 0 or Day 0 +56 | IM | Janssen Pharmaceutical | Phase 4 | [17] |
| 38 | Viral vector (replicating) | DeINS1-2019-nCoV-RBD-OPT1 (Intranasal flu-based-RBD) | 2 | Day 0 + 28 | IN | University of Hong Kong, Xiamen University and Beijing Wantai Biological Pharmacy | Phase 3 | I |
| 9 | Protein subunit | SARS-CoV-2 rS/Matrix M1-Adjuvant (Full length recombinant SARS CoV-2) | 2 | Day 0 + 21 | IM | Novavax | Phase 3 | [25] |
| 12 | Protein subunit | Recombinant SARS-CoV-2 vaccine (CHO cell) | 2-3 | Day 0 + 28 or | IM | Anhui Zhifei Longcom Biopharmaceutical + Institute of Microbiology, Chinese Academy of Sciences | Phase 3 | J |
| 22 | Protein subunit | VAT00008: SARS-CoV-2 S protein with adjuvant | 2 | Day 0 + 21 | IM | Sanofi Pasteur + GSK | Phase 3 | K |
| 29 | Protein subunit | CpG 1018/Alum-adjuvanted recombinant SARS-CoV-2 trimeric S-protein subunit vaccine (SCB-2019) | 2 | Day 0 + 21 | IM | Clover Biopharmaceuticals Inc./Dynavax | Phase 3 | L |
| 30 | Protein subunit | COVAX-19® Recombinant spike protein + adjuvant | 2 | Day 0 + 21 | IM | Vaxine Pty Ltd./CinnaGen Co. | Phase 3 | M |
| 31 | Protein subunit | MVC-COV1901 (Spike-2P protein + adjuvant CpG 1018) | 2 | Day 0 + 28 | IM | Medigen Vaccine Biologics + Dynavax + National Institute of Allergy and Infectious Diseases (NIAID) | Phase 4 | N |
| 33 | Protein subunit | FINLAY-FR-2 anti-SARS-CoV-2 vaccine (RBD chemically conjugated to tetanus toxoid plus adjuvant) | 2 | Day 0 + 28 | IM | Instituto Finlay de Vacunas | Phase 3 | O |
| 34 | Protein subunit | EpiVacCorona (EpiVacCorona vaccine based on peptide antigens for the prevention of COVID-19) | 2 | Day 0 + 21 | IM | Federal Budgetary Research Institution State Research Center of Virology and Biotechnology "Vector" | Phase 3 | P |
| 35 | Protein subunit | RBD (baculovirus production expressed in Sf9 cells) recombinant SARS-CoV-2 vaccine (Sf9 Cell) | 2 | Day 0 + Day 21 + Day 42 | IM | West China Hospital + Sichuan University | Phase 3 | Q |
| 55 | Protein subunit | CIGB-66 (RBD+aluminium hydroxide) | 3 | Day 0 + 14 + 28 | IM | Center for Genetic Engineering and Biotechnology (CIGB) | Phase 3 | R |
| 57 | Protein subunit | BECOV2 | 2 | Day 0 + 28 | IM | Biological E. Limited | Phase 3 | S |
| 60 | Protein subunit | Recombinant Sars-CoV-2 spike protein, aluminum adjuvanted (Nanocovax) | 2 | Day 0 + 21 | IM | Nanogen Pharmaceutical Biotechnology | Phase 3 | T |
| 61 | Protein subunit | Recombinant protein vaccine S-268019 (using Baculovirus expression vector system) | 2 | Day 0 + 21 | IM | Shionogi | Phase 3 | U |
| 65 | Protein subunit | GBP510, a recombinant surface protein vaccine with adjuvant AS03 (aluminium hydroxide) | 2 | Day 0 + 28 | IM | SK Bioscience Co., Ltd. and CEPI | Phase 3 | V |
| 66 | Protein subunit | Razi Cov Pars, recombinant spike protein | 3 | Day 0 + 21 +51 | IM and IN | Razi Vaccine and Serum Research Institute | Phase 3 | W |
| 91 | Protein subunit | Recombinant SARS-CoV-2 fusion protein vaccine (V-01) | 2 | Day 0 + 21 | IM | Livzon Pharmaceutical | Phase 3 | X |
| 106 | Protein subunit | RBD protein recombinant SARS-CoV-2 vaccine (Noora vaccine) | 3 | Day 0 + 21 + 35 | IM | Bagheiat-allah University of Medical Sciences/AmitisGen | Phase 3 | Y |
| 10 | RNA based vaccine | mRNA-1273 | 2 | Day 0 + 28 | IM | Moderna + National Institute of Allergy and Infectious Diseases (NIAID) | Phase 4 | [22] |
| 11 | RNA based vaccine | BNT162b2 (3 LNP-mRNAs ), also known as "Comirnaty" | 2 | Day 0 + 21 | IM | Pfizer/BioNTech + Fosun Pharma | Phase 4 | [23] |
| 13 | RNA based vaccine | CVnCoV vaccine | 2 | Day 0 + 28 | IM | CureVac AG | Phase 3 | Z |
| 40 | RNA based vaccine | SARS-CoV-2 mRNA vaccine (ARCoV) | 2 | Day 0 + 14 orDay 0 + 28 | IM | Academy of Military Science (AMS), Walvax Biotechnology and Suzhou Abogen Biosciences | Phase 3 | AA |
| 78 | RNA based vaccine | mRNA-1273.351. | 3 | Day 0 or Day 0 + 28 | IM | Moderna + National Institute of Allergy and Infectious Diseases (NIAID) | Phase 4 | BB |
| 115 | RNA based vaccine | ARCT-154 mRNA vaccine | 2 | Day 0 + 28 | IM | Arcturus Therapeutics, Inc. | Phase 3 | CC |
| 16 | DNA based vaccine | INO-4800+electroporation | 2 | Day 0 + 28 | ID | Inovio Pharmaceuticals + International Vaccine Institute + Advaccine (Suzhou) Biopharmaceutical Co., Ltd | Phase 3 | [20] |
| 18 | DNA based vaccine | nCov vaccine | 3 | Day 0 + 28 + 56 | ID | Zydus Cadila | Phase 3 | DD |
| 41 | Virus like particle | Coronavirus-Like Particle COVID-19 (CoVLP) | 2 | Day 0 + 21 | IM | Medicago Inc. | Phase 3 | EE |
| 53 | Live attenuated virus | COVI-VAC | 1-2 | Day 0 orDay 0 + 28 | IN | Codagenix/Serum Institute of India | Phase 3 | CC |